MCRB — Seres Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1609809 ·
Last close
$3.52
Market Cap
$35.36M
52W High
$29.98
52W Low
$3.50
ADV30
57,297
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 736,000 | 736,000 | -15,466,000 | 4,581,000 | 101,588,000 | 15,594,000 | 67,054,000 |
| Mar 2026 | 358,000 | 358,000 | -20,907,000 | -19,913,000 | 117,618,000 | 29,834,000 | 91,119,000 |
| Dec 2025 | 789,000 | 197,000 | -19,377,000 | -15,335,000 | 138,193,000 | 45,766,000 | 93,975,000 |
| Sep 2025 | 0 | -736,000 | -22,477,000 | 8,204,000 | 143,473,000 | 47,638,000 | 99,776,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-51,258,000
Investing CF
$187,000
Financing CF
$14,861,000
CapEx
$-252,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.94
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-987,735,000
Inventory
—
Receivables
$25,274,000
ST Investments
—
EBIT TTM
$21,440,000
Pretax Income TTM
$-22,463,000
Interest Exp TTM
$0
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,883,000
EBITDA
$-74,778,000
Free Cash Flow
$-64,600,876
Enterprise Value
$90,855,720
Total Cash
$15,594,000
Total Debt
$56,644,000
Shares Out
10,044,781
Trailing EPS
$-2.42
Book Value
$3.51
ROE
-66.6%
ROA
-39.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 789,000 | -93,971,000 | 5,696,000 | 138,193,000 | 93,975,000 | 44,218,000 | 1,117,000 |
| Dec 2024 | 0 | -121,315,000 | 136,000 | 139,810,000 | 126,026,000 | 13,784,000 | -148,609,000 |
| Dec 2023 | 0 | -195,097,000 | -113,724,000 | 358,600,000 | 403,456,000 | -44,856,000 | -117,354,000 |
| Dec 2022 | 0 | -179,914,000 | -250,157,000 | 348,784,000 | 338,001,000 | 10,783,000 | -228,816,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.95
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.00 · spot: $3.52 · call volume: 35 · put volume: 2Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PYRGF | PyroGenesis Canada Inc. | $35.77M | $0.16 | — |
| FLNA | FILANA THERAPEUTICS, INC. | $36.23M | $0.75 | — |
| KPTI | Karyopharm Therapeutics Inc. | $36.74M | $1.62 | — |
| NNVC | NANOVIRICIDES, INC. | $36.76M | $1.44 | — |
| RMTI | ROCKWELL MEDICAL, INC. | $33.73M | $8.37 | — |
News headlines (Yahoo Finance, 1h cache)
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-08 22:00 · Yahoo
Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences
2026-09-07 08:27 · Yahoo
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
2026-09-01 11:00 · Yahoo
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
2026-08-05 11:00 · Yahoo
Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
2026-07-10 18:02 · Yahoo
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
2026-06-25 11:00 · Yahoo
We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate
2026-06-13 12:57 · Yahoo
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
2026-05-12 11:00 · Yahoo
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
2026-05-04 11:00 · Yahoo
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
2026-04-20 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.